Abstract
In light of the recent demonstration that intragraft mechanisms appear to be important in regulating virtually all phases of the rejection response, and that local immunosuppression achieves the goals of preventing rejection with reduced systemic drug exposure and toxicity in rodent and canine models, it is clear that the concept deserves continued exploration and eventual clinical application. Pharmaceutical companies must become interested in the development of immunosuppressant prodrugs that are selectively activated in and then rapidly eliminated by the transplanted organ of interest or the systemic circulation, and in the development of active agents that are pharmacokinetically tailored for pump-based local administration to a given target organ. New methods of local drug delivery, such as nanoparticle and magnetically-localized therapeutic carriers, should be applied to organ transplantation. Finally, research efforts must be continued towards the goal of utilizing gene transfer techniques to obtain stable, long-term local immunosuppression of immediately-vascularized solid-organ transplants in large animals and man.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Rights and permissions
Copyright information
© 1996 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Gruber, S.A. (1996). Conclusion. In: Local Immunosuppression of Organ Transplants. Medical Intelligence Unit. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-22105-1_20
Download citation
DOI: https://doi.org/10.1007/978-3-662-22105-1_20
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-662-22107-5
Online ISBN: 978-3-662-22105-1
eBook Packages: Springer Book Archive